Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells

Transplantation

Volumn 91, Issue 12, 2011, Pages 1412-1416

  Wu, Kang Hsi ^a,b   Chan, Chin Kan ^c,d   Tsai, Chris ^e   Chang, Yu Hsiang ^f   Sieber, Martin ^e   Chiu, Tsan Hung ^a   Ho, Ming ^a   Peng, Ching Tien ^a,g   Wu, Han Ping ^h,i   Huang, Jing Long ^j  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b University Hospital   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d TAO YUAN GENERAL HOSPITAL   (Taiwan)

^e Bionet Corp   (Taiwan)

^f KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g ASIA UNIVERSITY   (Taiwan)

^h BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

^j CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

more..

Author keywords

Acute graft versus host disease; Mesenchymal stem cells; Umbilical cord

Indexed keywords

5' NUCLEOTIDASE; BETA1 INTEGRIN; BILIRUBIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENDOGLIN; ETOPOSIDE; HERMES ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; MICROSOMAL AMINOPEPTIDASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THY 1 ANTIGEN; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; APLASTIC ANEMIA; ARTICLE; BLOODY DIARRHEA; CASE REPORT; CELL PROLIFERATION; CELL STRUCTURE; CHILD; COCULTURE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE EXACERBATION; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; LEUKEMIA REMISSION; MACULOPAPULAR RASH; MALE; MESENCHYMAL STEM CELL; NON INVASIVE PROCEDURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; STEM CELL; UMBILICAL CORD BLOOD STEM CELL; VOMITING;

BONE MARROW CELLS; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FETAL BLOOD; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; STEROIDS; TREATMENT OUTCOME;

EID: 79958770457     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821aba18     Document Type: Article

References (22)

1. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499.
2. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third-party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439.
3. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390.
4. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579.
5. Koç ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307.
6. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLAidentical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389.
7. Poloni A, Leoni P, Buscemi L, et al. Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia 2006; 20: 329.
8. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007; 21: 1733.
9. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem cell transplantation. Blood 2007; 110: 2764.
10. Macmillan ML, Blazar BR, DeFor TE, et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I-II clinical trial. Bone Marrow Transplant 2009; 43: 447.
11. Secco M, Zucconi E, Vieira NM, et al. Multipotent stem cells from umbilical cord: Cord is richer than blood! Stem Cells 2008; 26: 146.
12. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109: 4119.
13. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11.
14. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graftversus- host diseases in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295.
15. Yañez R, Lamana ML, García-Castro J, et al. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006; 24: 2582.
16. Chen K, Wang D, Du WT, et al. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol 2010; 135: 448.
17. Wang M, Yang Y, Yang D, et al. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology 2009; 126: 220.
18. Chang CJ, Yen ML, Chen YC, et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 2006; 24: 2466.
19. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143.
20. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114.
21. Fu YS, Cheng YC, Lin MY, et al. Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: Potential therapeutic application for Parkinsonism. Stem Cells 2006; 24: 115.
22. Chao YH, Peng CT, Harn HJ, et al. Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia. Ann Hematol 2010; 89: 715.